Research suggests that statins affect the regulation of arterial blood pressure (BP), however, the mechanisms remain obscure. We maintained male, 12-week-old, Sprague-Dawley rats on tap water (controls) or water containing simvastatin or pravastatin for 4 weeks. Subsequently, we measured mean arterial blood pressure and heart rate at baseline and after intravenous infusion of either saline or angiotensin II (Ang II). Additionally, we tested baroreflex function and the effect of statins on vasoconstrictor response to Ang II on isolated femoral artery branches. Controls and simvastatin and pravastatin groups showed a significant increase in mean arterial BP and heart rate in response to Ang II. The increase was significantly smaller in the simvastatin group than in controls and in the pravastatin group. In contrast, when pretreated with hexamethonium, a ganglionic blocker, simvastatin and pravastatin groups showed a similar hypertensive response to Ang II, which was smaller than in controls. Likewise, the Ang II-induced vasoconstrictor response of femoral artery branches was comparable between simvastatin and pravastatin groups and smaller than in controls. We found no effect of statins on the baroreflex. This study shows that simvastatin and pravastatin differ in their effects on the Ang II-dependent mechanisms controlling BP.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jash.2014.09.008 | DOI Listing |
Clin Neurol Neurosurg
January 2025
Department of Neurology, Milton S. Hershey Medical Center, Penn State University College of Medicine, Hershey, PA, USA. Electronic address:
Introduction: Acute large vessel occlusions (LVOs) account for up to one-third of acute ischemic strokes (AIS) and are associated with high mortality and severe functional deficits. Animal model research suggests that statins may have a protective effect on vessel wall injury during endovascular thrombectomy (EVT). We conducted a retrospective observational study to assess the impact of statin use on clinical outcomes post-EVT in AIS patients with LVOs.
View Article and Find Full Text PDFEur J Hum Genet
December 2024
Department of Family Medicine, Public Health and Primary Care (PHEG), Mayo Clinic, Rochester, MN, USA.
Aligned with the mission of the Dutch Pharmacogenetics Working Group (DPWG) to promote the implementation of pharmacogenetics (PGx), this guideline is specifically designed to optimize pharmacotherapy of cholesterol lowering medication (statins) and glucose lowering medication (sulfonylureas). The SLCO1B1 c.521 T > C variant reduces the activity of the SLCO1B1 transporter involved in statin transport out of the blood into the liver.
View Article and Find Full Text PDFBMJ Open Diabetes Res Care
December 2024
Ludeman Family Center for Women's Health Research, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Introduction: Diabetes mellitus (DM) is increasingly recognized as a possible consequence of statin therapy. Secondary analysis of randomized clinical trials and limited observational cohort analyses have suggested that women may be more likely than men to experience statin-associated DM. No analyses of real-world drug safety data addressing this question have been published.
View Article and Find Full Text PDFBr J Gen Pract
November 2024
London School of Hygiene and Tropical Medicine Faculty of Epidemiology and Population Health, Department of Non-communicable Disease Epidemiology, London, United Kingdom.
Front Endocrinol (Lausanne)
November 2024
Department of Genetics and Bioinformatics, Dasman Diabetes Institute, Kuwait City, Kuwait.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!